OTTAWA, Nov. 15, 2012 /CNW/ - Representatives of Canada's Research-Based Pharmaceutical Companies (Rx&D) will be available to discuss newly released reports on the industry's commitment to life sciences research, its overall contribution to the economy and the role of pharmaceuticals in achieving better health outcomes.
Rx&D commissioned analysis from KPMG, RiskAnalytica, and SECOR in 2012. The three reports were streamlined into one document: "Saving Lives - Transforming Care", which outlines how Canada's research-based pharmaceutical companies support the Canadian economy and contribute to the health and well-being of Canadians. The documents are available at http://www.canadapharma.org/view.asp?x=342.
|What:||Technical briefing with senior industry leaders|
|Where:||National Press Theatre|
|When:||Tuesday, November 20, 2012|
Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.
SOURCE: CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)
For further information:
Telephone: 613-236-0455 (extension 831)